Clinical Trial Update: Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of zanubrutinib, obinutuzumab, and sonrotoclax in previously untreated chronic lymphocytic leukemia and small lymphocytic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Sonrotoclax
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL) | Phase 2 | Status: RECRUITING